CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores-Reference-Cited by-同舟云学术

CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores

Published:2013-12-20 Issue:1 Volume:77 Page:160-169
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Albarmawi Albader¹,Czock David¹,Gauss Annika²,Ehehalt Robert²,Lorenzo Bermejo Justo³,Burhenne Jürgen¹,Ganten Tom M.²,Sauer Peter²,Haefeli Walter E.¹

Affiliation:

1. Department of Clinical Pharmacology and Pharmacoepidemiology; University of Heidelberg; Heidelberg Germany

2. Department of Internal Medicine IV, Gastroenterology, Infectious Diseases, and Intoxication; University Hospital Heidelberg; Heidelberg Germany

3. Institute of Medical Biometry and Informatics; University of Heidelberg; Heidelberg Germany

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.12182/fullpdf

Reference36 articles.

1. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction;Verbeeck;Eur J Clin Pharmacol,2008

2. Dose adjustment in patients with liver disease;Delcò;Drug Saf,2005

3. Dosage adjustment for hepatic dysfunction based on Child-Pugh scores;Spray;Am J Health Syst Pharm,2007

4. Dosage adjustments in hepatic dysfunction;Amariles;Am J Health Syst Pharm,2007

5. Food and Drug Administration Guidance for industry. Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling 2003 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072123.pdf

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of voriconazole in the treatment of invasive pulmonary aspergillosis in patients with liver failure: study protocol for a randomized controlled clinical trial;Trials;2023-12-17

2. Hepatic Impairment as a Risk Factor for Drug Safety: Suitability and Comparison of Four Liver Scores as Screening Tools;Journal of Clinical Medicine;2023-10-27

3. Medications for alcohol use disorder promote abstinence in alcohol-associated cirrhosis: Results from a systematic review and meta-analysis;Hepatology;2023-08-25

4. Review of the role of statins in cirrhosis and portal hypertension;Clinical Liver Disease;2023-04-27

5. Impact of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation;British Journal of Clinical Pharmacology;2023-02